Inhibitors of apoptosis
AssigneeAmgen Inc.
InventorsMike Rothe, David V. Goeddel
Life of this patent
Estimating the term…
Loading patent…
AssigneeAmgen Inc.
InventorsMike Rothe, David V. Goeddel
Estimating the term…
The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular, at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis; for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes. The invention includes methods of using the subject compositions in therapy, in diagnosis and in the biopharmaceutical industry.
A pharmaceutical composition comprising a polynucleotide which specifically hybridizes with SEQ ID NO:1 or 3, and inhibits cellular expression of c-IAP1 or c-IAP2 in vitro.
Dependencies are inferred from the claim text.